Rapid Test Kit Market

Rapid Test Kit Market for COVID-19
Market By Test Type (Rapid Antigen
Test, Rapid Antibody Test, Others), By
End-Users (Hospitals & Clinics.
Diagnostics Laboratory, Home Care,
Others), Forecasts, 2020-2027
www.reportsanddata.com

www.reportsanddata.com
Market Summary
The global rapid test kit market for COVID-19 is expected to reach USD 3.70 Billion by 2027, according to
a new report by Reports and Data. The initial diagnosis of diseases, as well as accuracy, play an
instrumental role in the treatment of patients. Rapid test kits are in vitro diagnostics methods
implemented individually or in a small series that involve manual procedures and have been developed
to provide a rapid result. For the purpose testing COVID-19, rapid test kit may require about 10 to 30
minutes to give a result as compared to about hours of molecular tests performed in large series, or it
might take even more time samples have to be transported to a remotely located testing laboratory. The
rapid tests for COVID-19 are fairly simple to perform and infer and hence need limited test operator
training and may be used either for usage in hospital laboratories or close to the point-of-care.
The COVID-19 pandemic is affecting the worldwide population in radical ways. In several nations,
geriatric people are facing the maximum dangers and challenges in dire situation. Even though people of
all age groups are at risk of getting infected by COVID-19, elderly people face a substantial risk of getting
severely ill in the event of contracting COVID-19, owing to physiological changes that follow with aging
and probable underlying health conditions. More than 95.0% of deaths owing to the disease occurred in
people aged than 60 years. Over 50.0% of all casualties involved people aged 80 years or older. It has
been found that 8 out of 10 fatalities are happening in individuals with no less than one comorbidity,
especially in those with hypertension, cardiovascular disease, and diabetes, as well as with other chronic
underlying conditions.

www.reportsanddata.com
Further key findings from the report suggest
• By test type, the rapid antigen test is likely to hold substantial market share in 2020 and is expected
to grow at a rate of -21.1% in the forecast period. The basis rapid antigen test is the particular binding
of an antigen (glycoprotein or protein) to an antibody. Antigen assays are usually more cost-effective
as compared to either molecular or culture techniques; nevertheless, they do not increase their target
as culture increases communicable organisms or as polymerase chain reaction amplifies nucleic acid.
Therefore, this test is frequently less sensitive as compared to other methods.
• By end-users, hospitals and clinics are likely to contribute to the largest market share in 2020 and is
expected to grow at a rate of -21.0% the forecast period. The factors including well-resourced
operating & diagnostic rooms, higher purchasing power, the existence of highly skilled healthcare
professionals, and improved health coverage for hospital-based healthcare services from several
private and group insurance plans, among others, are responsible for the high market share of
hospitals.
• The market in the Asia Pacific region is estimated to grow at the fastest rate of -20.0% in the forecast
period, attributed to the presence of a large population in the countries such as India in the region
pushing the governments to order rapid test kits for COVID-19 in huge quantity to contain the spread
of the disease.

www.reportsanddata.com
• In April 2020, a minimum of four conglomerate producers of COVID-19 rapid test kits are putting
efforts to supply over a million diagnostic kits to the Indian sub-continent, as the nation looks to
produce testing for the novel coronavirus. The Siemens, Thermo Fisher Scientific, Altona, and Seegene
are all anticipated to commence supplying COVID-19 test kits.
• Key participants include Abbott Laboratories, Acumen Research Laboratories, BioMedomics, Biolidics,
LabCorp, ThermoFisher, CTK Biotech, Biomaxima, Beijing Tigsun Diagnostics Co. Ltd., and Getein
Biotech, among others.
• In March 2020, Aperiomics launched a reverse transcription-polymerase chain reaction in the U.S.
meant for the qualitative detection of coronavirus, with the capability to process around 1,000 tests
per week, and the firm can offer test results in 48 to 72 hours of getting a sample. The company
announced to double its COVID-19 PCR testing capacity in the month of April, with support from
Howard Hughes Medical Institute's Janelia Research Campus.
• In March 2020, Arup Laboratories launched an innovative test kit for the novel COVID-19 and
instigated testing; the molecular diagnostic kit is meant to detect RNA of the coronavirus; the test is
done using a qualitative polymerase chain reaction technique.
Get Free Report Sample @ https://www.reportsanddata.com/sample-enquiry-form/2964

• North America
• U.S
• Europe
• U.K
• France
www.reportsanddata.com
For the purpose of this report, Reports and Data have segmented the global rapid test kit market for
COVID-19 on the basis of test type, end-users, and region:
Test Type Outlook (Revenue, USD Million; 2020-2027)
• Rapid Antigen Test
• Rapid Antibody Test
• Others
End-Users Outlook (Revenue, USD Million; 2020-2027)
• Hospitals & Clinics
• Diagnostics Laboratory
• Home Care
• Others
Regional Outlook (Revenue, USD Million; 2020-2027)

www.reportsanddata.com
• Asia Pacific
• China
• India
• Japan
• Latin America
• Brazil
• MEA
Browse Complete Report “Rapid Test Kit Market for COVID-19 Market By Test Type (Rapid
Antigen Test, Rapid Antibody Test, Others), By End-Users (Hospitals & Clinics. Diagnostics
Laboratory, Home Care, Others), Forecasts, 2020-2027” @
https://www.reportsanddata.com/report-detail/rapid-test-kit-market

www.reportsanddata.com
About Us
Reports and Data is a market research and
consulting company that provides syndicated research
reports, customized research reports, and consulting
services. Our solutions purely focus on your purpose to
locate, target and analyze consumer behavior shifts
across demographics, across industries and help client’s
make a smarter business decision.
We offer market intelligence studies ensuring relevant
and fact-based research across a multiple industries
including Healthcare, Technology, Chemicals, Power, and
Energy. We consistently update our research offerings to
ensure our clients are aware about the latest trends
existent in the market. Reports and Data has a strong
base of experienced analysts from varied areas of
expertise.
Contact US
John Watson
Head of Business Development
Reports And Data | Web:
www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com